Cutting-edge research initiatives to develop new treatments to tackle antimicrobial resistance (AMR) – known as the ‘silent killer’ – will receive a cash injection of up to £39 million from the UK government’s Global AMR Innovation Fund (GAMRIF).
Of this new funding package, up to £24 million over 4 years has been awarded to bolster the UK’s partnership with CARB-X – a global AMR research initiative – to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life-threatening drug-resistant infections and prevent death and disease across the world.
